BIOMEBANK
LIVE

Serial Number

79378921

Owner

COST-BRY PTY LTD

Attorney

Jocelyn C. Smith

Filing Date

Aug 23, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIOMEBANK Trademark

Serial Number: 79378921 • Registration: 8097613

BIOMEBANK is a trademark filed by COST-BRY PTY LTD on August 23, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

COST-BRY PTY LTD (4 trademarks)

Level 3, 21-24 North Terrace

Entity Type: 99

Trademark Details

Filing Date

August 23, 2023

Registration Date

January 13, 2026

Published for Opposition

June 10, 2025

Goods & Services

Biological research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; bacteriological research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; biotechnology research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; biotechnology testing of materials in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; advisory services relating to scientific research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; technology advisory services related to biotechnological engineering research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; biochemistry research services in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of biotechnology animal genetics research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; medical research services in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research for medical purposes in the field of cancerous diseases for the development, testing, and treatment of cultured microbial therapies; scientific research, namely, preparation of reports in the field of in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; Technical research, in the field of in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research, namely, conducting statistical scientific studies in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; providing information in the field of scientific and technological research and design services via a web site in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; provision of information relating to scientific research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; provision of medical research services in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; rental of scientific research facilities in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; research and development of new products in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of bacteriology for the development, testing, and treatment of cultured microbial therapies; scientific research and development of new products in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of biology for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of genetics for the development, testing, and treatment of cultured microbial therapies; technological research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; providing scientific information in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies; scientific research in the field of microbiology, bacteriology and microbiome therapy for the development, testing, and treatment of cultured microbial therapies.

Biological agents, namely, bacterial fungicides, fungicides, weedkillers, herbicides, insecticides, parasiticides, and pesticides; biological control agents being pesticides; biological preparations for medical purposes, namely, the treatment of cancer; biological preparations for pharmaceutical purposes, namely, the treatment of cancer; biological preparations for use in cell cultures in biotechnology for medical purposes; biological preparations for use in cell cultures for medical purposes; biological products being reagents for medical use; biological substances being reagents for medical use; biological tissue cultures for medical purposes; biological reagants for use in biological processing for medical purposes; bacteriological culture mediums for medical purposes or veterinary purposes; bacteriological cultures for medical and veterinary use; bacteriological preparations for medical and veterinary use; diagnostic test reagants for medical use in detecting allergenic substances

Medical advisory services, namely, advisory services relating to medical services for the testing and treatment of cultured microbial therapies; alternative medical services for the testing and treatment of cultured microbial therapies; charitable services, namely, providing medical services to underserved communities for the testing and treatment of cultured microbial therapies; medical services in the field of gastroenterology for the testing and treatment of cultured microbial therapies; medical diagnostic services in the nature of testing and analysis services for the testing and treatment of cultured microbial therapies; medical advisory services, namely, advisory services relating to medical problems for the testing and treatment of cultured microbial therapies.

Filing History

FINAL DISPOSITION NOTICE SENT TO IB
Aug 5, 2026 FICS
FINAL DISPOSITION PROCESSED
Aug 5, 2026 FIMP
CORRECTION UNDER SECTION 7 - PROCESSED
Aug 5, 2026 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 1, 2026 APRE
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 13, 2026 FICR
TEAS SECTION 7 REQUEST RECEIVED
Mar 2, 2026 ES7R
POST PUBLICATION AMENDMENT – NOT ENTERED
Jan 14, 2026 CHPN
ASSIGNED TO PETITION STAFF
Jan 13, 2026 APET
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 13, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 13, 2026 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Dec 18, 2025 ETOP
TEAS POST PUBLICATION AMENDMENT RECEIVED
Nov 10, 2025 EPPA
NEW REPRESENTATIVE AT IB RECEIVED
Aug 28, 2025 NREP
EXTENSION OF TIME TO OPPOSE RECEIVED
Jul 7, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 10, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 10, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 4, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2025 CNSA
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 1, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 12, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Feb 12, 2025 OPNR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 7, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 6, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 6, 2025 TROA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Aug 30, 2024 ADCH
REFUSAL PROCESSED BY IB
Jul 28, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 6, 2024 RFCS
REFUSAL PROCESSED BY MPU
Jul 6, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 5, 2024 RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 5, 2024 RFCR
NON-FINAL ACTION WRITTEN
May 17, 2024 CNRT
ASSIGNED TO EXAMINER
Apr 24, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 19, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 15, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 14, 2023 REPR